On May 30, 2014 Oragenics Inc (NYSEMKT:OGEN) held its Annual meeting of Shareholders (the “Meeting”), at which Meeting, the Company’s shareholders authorized the amendment to our Amended and Restated Articles of Incorporation (the “Amendment”) to increase the number of authorized common stock to 100,000,000 shares, upon a determination by our Board of Directors that such an increase is in the best interests of our Company and our shareholders. Oragenics Inc (NYSEMKT:OGEN) stock performance was 5.96% in last session and finished the day at $2.49. Traded volume was 104,681.00million shares in the last session and the average volume of the stock remained 28.70K shares. The beta of the stock remained 0.23. Oragenics Inc (NYSEMKT:OGEN) insider ownership is 0.20%.

Kindred Biosciences Inc (NYSE:KIN) lock-up period is set to end on Tuesday, June 10th. Kindred Biosciences had issued 7,500,000 shares in its initial public offering on December 12th, American Banking & Market News reports. The total size of the offering was $52,500,000 based on an initial share price of $7.00.Kindred Biosciences Inc (NASDAQ:KIN) rose 10.87 percent to $19.48 Tuesday on volume of 119,220.00million shares. The intra-day range of the stock was $17.60 to $19.74. Kindred Biosciences Inc (NASDAQ:KIN) has a market capitalization of $383.31million.

Revance Therapeutics Inc (NASDAQ:RVNC) announced its earnings results on 13 May 2014. The company reported ($1.93) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.87) by $1.06, AnalystRatings.Net reports. Revance Therapeutics Inc (NASDAQ:RVNC)’s stock on June 10, 2014 reported a increase of 7.21% to the closing price of $30.72. Its fifty two weeks range is $21.00 -$39.86. The total market capitalization recorded $574.38million. The overall volume in the last trading session was 138,609.00million shares. In its share capital, RVNC has 18.70million outstanding shares.

Stemline Therapeutics Inc (NASDAQ:STML) announced its earnings results on 22 May 2014. The company reported ($0.70) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.72) by $0.02, AmericanBankingNews.com reports. On Tuesday, shares of Stemline Therapeutics Inc (NASDAQ:STML) advanced 8.63% to close the day at $16.62. Company monthly performance is recorded as 16.71%. Stemline Therapeutics Inc (NASDAQ:STML) quarterly revenue growth is -31.66%.
Aastrom Biosciences, Inc. (NASDAQ:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, on 04 June 2014 announced the appointment of Gerard Michel, MS, MBA, as chief financial officer and vice president, corporate development. Aastrom Biosciences Inc (NASDAQ:ASTM) stock performance was 5.49% in last session and finished the day at $4.42. Traded volume was 258,579.00million shares in the last session and the average volume of the stock remained 493.87K shares. The beta of the stock remained 0.94. Aastrom Biosciences Inc (NASDAQ:ASTM) insider ownership is 3.27%.